RxDoctor Payments Data

Nhu Nguyen, MD

Ophthalmology · Houston, TXNPI 1811959216

Payments from drug & device makers

$2,822in general payments, 2019–2025

Across 98 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$623
  • Bausch & Lomb Americas Inc.$363
  • AstraZeneca$283
  • Novartis$264
  • AbbVie$237
  • Sun Pharmaceutical Industries Inc.$217
  • plus $835 from 15 others

What the payments were for

  • Food & beverage$2,80399%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,822 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$76,174
Medicare patients
153
Services billed
929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine755$296,200
XiidraLifitegrast422$294,004
LumiganBimatoprost660$220,272
VyzultaLatanoprostene Bunod157$45,604
Cyclosporine201$28,976
SimbrinzaBrinzolamide/Brimonidine Tart104$20,992
MieboPerfluorohexyloctane/Pf27$20,232
Alphagan PBrimonidine Tartrate41$19,607
RocklatanNetarsudil Mesylat/Latanoprost45$19,264
RhopressaNetarsudil Mesylate48$17,167
VascepaIcosapent Ethyl108$9,845
CombiganBrimonidine Tartrate/Timolol25$9,072
CequaCyclosporine14$8,102
Latanoprost1,208$6,295
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol66$5,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$237$545,1521,481 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$363$359,839606 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$17$36,43093 claims
AlconSimbrinza, Azopt$174$24,939115 claims
Sun Pharmaceutical Industries Inc.Cequa$217$8,10214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →